Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL8343678 | 1.00 | TSHR (0.73) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL28284156 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL155636 | 0.95 | TSHR (0.80) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL11297734 | 0.91 | TSHR (0.61) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL11299765 | 0.91 | TSHR (0.61) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL25434941 | 0.90 | TSHR (0.73) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL4621936 | 0.90 | — | — | |
| Sulfuric Acid SCHEMBL11543101 | 0.90 | — | — | |
| Sulfuric Acid SCHEMBL5013134 | 0.90 | — | — | |
| Sulfuric Acid SCHEMBL9719509 | 0.90 | TSHR (0.73) | TSHRMEN1ALDH1A1KMT2ACA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116803379-A | Indometazole immediate release/sustained release multilayer tablet and use thereof in the treatment of attention deficit/hyperactivity disorder (ADHD) | NLS-1 制药公司 | 2023-09-26 | — | — | CN | claimed |
| CN-109152740-A | An immediate/sustained release multi-layer tablet of mazindol and its use in the treatment of attention deficit/hyperactivity disorder (ADHD) | NLS-1制药公司 | 2019-01-04 | — | — | CN | claimed |
| CN-113853374-B | Compound forms with enhanced bioavailability and formulations thereof | PTC医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-112739334-B | Crystalline malonic acid adrenergic salt | 拜欧西亚制药公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-117642381-A | Fatty Acid Amide Hydrolase (FAAH) cleavable prodrugs of brain targeting actives in combination with peripherally restricted FAAH inhibitors | 速通医疗公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117597122-A | Fatty Acid Amide Hydrolase (FAAH) cleavable prodrugs of thyromimetics and combinations with peripherally restricted FAAH inhibitors | 速通医疗公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-116803379-A | Indometazole immediate release/sustained release multilayer tablet and use thereof in the treatment of attention deficit/hyperactivity disorder (ADHD) | NLS-1 制药公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-113853374-A | Compound forms and formulations thereof with enhanced bioavailability | PTC医疗公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-112739334-A | Crystalline adrenaline malonate | 拜欧西亚制药公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-111343979-A | Equine indole treatment for heroin dependence and substance use disorders | NLS-1制药公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111278433-A | Nilaparib formulations | 特沙诺有限公司 | 2020-06-12 | — | — | CN | disclosed |
| CN-1891209-A | Eplerenone crystalline form exhibiting enhanced dissolution rate | PHARMACIA CORP (US) | 2007-01-10 | — | — | CN | disclosed |
| CN-1679556-A | Valdecoxib compositions | PHARMACIA CORP (US) | 2005-10-12 | — | — | CN | disclosed |
| CN-1203852-C | Victorcy composition | PHARMACIA CORP (US) | 2005-06-01 | — | — | CN | disclosed |
| CN-1557833-A | Crystalline form of eplerenone exhibiting enhanced dissolution rate | — | 2004-12-29 | — | — | CN | disclosed |
| CN-1152886-C | Crystalline form of eplerenone exhibiting enhanced dissolution rate | — | 2004-06-09 | — | — | CN | disclosed |
| CN-1433427-A | Eplerenone crystalline form | PHARMACIA CORP (US) | 2003-07-30 | — | — | CN | disclosed |
| CN-1433308-A | Cyclooxygenase-2 inhibitor compositions having rapid on set therapeutic effect | PHARMACIA CORP (US) | 2003-07-30 | — | — | CN | disclosed |
| CN-1379669-A | Victorcy composition | PHARMACIA CORP (US) | 2002-11-13 | — | — | CN | disclosed |
| CN-1377365-A | Crystalline form of eplerenone exhibiting enhanced dissolution rate | PHARMACIA CORP (US) | 2002-10-30 | — | — | CN | disclosed |